Argenx Soars 13.5% on Strong Earnings, Analyst Upgrade

On July 31, 2025, Argenx's stock surged by 13.5% in pre-market trading, reflecting a significant boost in investor confidence.

Argenx's recent financial performance has been a key driver of its stock price. The company reported a substantial earnings per share (EPS) beat of $0.61 in the last quarter, which initially led to a 3.42% drop in share price. However, the long-term impact of this strong financial performance has been positive, as investors recognize the company's profitability and growth potential.

Deutsche Bank analyst Emmanuel Papadakis upgraded Argenx, highlighting its status as one of the most profitable biotech stocks to invest in. This endorsement from a reputable analyst has likely contributed to the recent surge in Argenx's stock price, as it reinforces the company's strong financial position and growth prospects.

Argenx's second-quarter global product net sales reached $949 million, with the VYVGART SC launch in CIDP progressing well, with more than 2,500 patients on treatment globally. This strong sales performance and the successful launch of new products have further bolstered investor confidence in the company's ability to generate revenue and drive growth.